Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TTH006
MIFTS: 49

Tooth Disease

Categories: Oral diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Tooth Disease

About this section

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 12 15
Tooth Diseases 44 73
Tooth Disorders 43

Classifications:

MalaCards categories:
Anatomical: Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1091
MeSH 44 D014076
SNOMED-CT 68 72722003
UMLS 73 C0040435
Sources

Summaries for Tooth Disease

About this section
MedlinePlus : 43 Your teeth are made of a hard, bonelike material. Inside the tooth are nerves and blood vessels. You need your teeth for many activities you may take for granted. These include eating, speaking and even smiling. But tooth disorders are nothing to smile about. They include problems such as cavities (also known as tooth decay), infections, and injuries. The most familiar symptom of a tooth problem is a toothache. Others include worn-down or loose teeth. It's important that you see a dentist if you have any problems with your teeth. Fortunately, you can prevent many tooth disorders by taking care of your teeth and keeping them clean.

MalaCards based summary : Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2j and charcot-marie-tooth disease, type 4b1, and has symptoms including snoring, halitosis and toothache. An important gene associated with Tooth Disease is MPZ (Myelin Protein Zero), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Acetylcholine and sodium fluoride have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and lung, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Tooth Disease

About this section

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2j 34.2 KIF1B MPZ
2 charcot-marie-tooth disease, type 4b1 34.2 GDAP1 MTMR2 SBF2
3 charcot-marie-tooth disease, type 4b2 34.2 GDAP1 MTMR2 SBF2
4 charcot-marie-tooth disease, type 4a 34.1 GDAP1 MTMR2 SBF2
5 charcot-marie-tooth disease, x-linked dominant, 1 34.1 GJB1 MPZ PMP22
6 charcot-marie-tooth disease, axonal, type 2d 34.1 GJB1 KIF1B MPZ PMP22
7 charcot-marie-tooth disease, demyelinating, type 4f 34.1 GDAP1 MTMR2 SBF2
8 charcot-marie-tooth disease, type 4j 34.1 FIG4 MTMR2 SBF2
9 charcot-marie-tooth disease, axonal, type 2a1 34.1 KIF1B MFN2
10 charcot-marie-tooth disease, type 4b3 34.1 GDAP1 MTMR2 SBF2
11 charcot-marie-tooth disease, axonal, type 2b 34.0 EGR2 GJB1 KIF1B MPZ PMP22
12 charcot-marie-tooth disease, axonal, type 2i 34.0 KIF1B MPZ
13 charcot-marie-tooth disease, axonal, type 2q 34.0 EGR2 MPZ
14 charcot-marie-tooth disease, type 4d 34.0 GDAP1 GJB1 MFN2 NDRG1 SH3TC2
15 charcot-marie-tooth disease, demyelinating, type 1b 34.0 EGR2 GJB1 KIF1B MPZ MTMR2 PMP22
16 charcot-marie-tooth disease, demyelinating, type 1f 34.0 GJB1 MPZ NEFL PMP22
17 charcot-marie-tooth disease, axonal, type 2f 34.0 GJB1 HSPB1 KIF1B MPZ
18 charcot-marie-tooth disease, axonal, type 2k 33.9 GDAP1 HSPB8 KIF1B MFN2
19 charcot-marie-tooth disease, demyelinating, type 1a 33.8 EGR2 GDAP1 GJB1 KIF1B MFN2 MPZ
20 charcot-marie-tooth disease, axonal, type 2l 33.8 HSPB1 HSPB8 KIF1B MPZ
21 charcot-marie-tooth disease type 2a 33.7 KIF1B MFN2
22 charcot-marie-tooth disease, demyelinating, type 1c 33.7 EGR2 GJB1 KIF1B LITAF MPZ NEFL
23 charcot-marie-tooth disease, demyelinating, type 1d 33.7 EGR2 GJB1 KIF1B MPZ MTMR2 NDRG1
24 charcot-marie-tooth disease, x-linked recessive, 3 33.7 GJB1 HSPB8
25 charcot-marie-tooth disease, axonal, type 2e 33.6 SBF2 PMP22 NEFL MTMR2 MPZ MFN2
26 charcot-marie-tooth disease and deafness 33.6 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
27 hereditary motor and sensory neuropathy, type iic 33.2 GDAP1 GJB1 KIF1B MFN2 MPZ NDRG1
28 roussy-levy hereditary areflexic dystasia 33.2 MPZ PMP22
29 neuropathy, hereditary motor and sensory, russe type 33.1 EGR2 NDRG1 SH3TC2
30 hypertrophic neuropathy of dejerine-sottas 32.7 EGR2 FGD4 GDAP1 GJB1 KIF1B LITAF
31 foot drop 32.1 MPZ PMP22
32 charcot-marie-tooth disease 32.1 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
33 neuropathy - hereditary 32.0 MPZ PMP22
34 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 31.9 SH3TC2 SBF2 PMP22 NDRG1 MTMR2 MPZ
35 congenital hypomyelination neuropathy 31.8 MPZ PMP22
36 charcot-marie-tooth hereditary neuropathy 31.8 MPZ PMP22
37 neuropathy, hereditary, with liability to pressure palsies 31.5 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
38 neuropathy 30.9 EGR2 GDAP1 GJB1 MFN2 MPZ PMP22
39 polyneuropathy 30.6 GDAP1 MPZ PMP22
40 sensory peripheral neuropathy 30.0 EGR2 FGD4 GDAP1 GJB1 LITAF MFN2
41 axonal neuropathy 30.0 GDAP1 LMNA MFN2 PMP22
42 cauda equina syndrome 29.8 EGR2 PMP22
43 early-onset glaucoma 29.8 MTMR2 SBF2
44 peripheral nervous system disease 29.6 EGR2 GDAP1 GJB1 KIF1B LITAF MFN2
45 amyotrophic lateral sclerosis 1 29.5 FIG4 HSPB1 HSPB8 NEFL
46 charcot-marie-tooth disease, type 4h 12.5
47 charcot-marie-tooth disease, type 4c 12.5
48 charcot-marie-tooth disease, axonal, type 2p 12.5
49 charcot-marie-tooth disease, axonal, type 2n 12.5
50 charcot-marie-tooth disease, axonal, type 2b1 12.5

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease
Sources

Symptoms & Phenotypes for Tooth Disease

About this section

UMLS symptoms related to Tooth Disease:


snoring, halitosis, toothache, poor dentition

GenomeRNAi Phenotypes related to Tooth Disease according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.37 GJB1
2 Decreased viability GR00107-A-1 10.37 HSPB8
3 Decreased viability GR00221-A-1 10.37 HSPB8
4 Decreased viability GR00221-A-4 10.37 HSPB8
5 Decreased viability GR00240-S-1 10.37 LMNA
6 Decreased viability GR00301-A 10.37 HSPB8
7 Decreased viability GR00381-A-1 10.37 FGD4 FIG4 HSPB1 LRSAM1 MPZ SH3TC2
8 Decreased viability GR00381-A-3 10.37 MPZ
9 Decreased viability GR00402-S-2 10.37 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
10 no effect GR00402-S-1 9.62 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB1
11 Increased gamma-H2AX phosphorylation GR00053-A 9.56 EGR2 GJB1 HSPB1 LMNA MPZ NDRG1

MGI Mouse Phenotypes related to Tooth Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
2 homeostasis/metabolism MP:0005376 10.13 EGR2 GDAP1 GJB1 HSPB1 HSPB8 KIF1B
3 cellular MP:0005384 10.11 EGR2 GDAP1 GJB1 HSPB1 HSPB8 LITAF
4 mortality/aging MP:0010768 9.97 EGR2 FIG4 GJB1 HSPB8 KIF1B LMNA
5 limbs/digits/tail MP:0005371 9.86 EGR2 FIG4 GDAP1 KIF1B LMNA MED25
6 muscle MP:0005369 9.56 FIG4 HSPB8 KIF1B LMNA MFN2 NDRG1
7 nervous system MP:0003631 9.55 EGR2 FGD4 FIG4 GDAP1 GJB1 KIF1B
Sources

Drugs & Therapeutics for Tooth Disease

About this section

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 441)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
2 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7681-49-4
3
Glycerol Approved, Investigational Phase 4 56-81-5 753
4
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
5
Tea tree oil Approved Phase 4,Not Applicable
6
Ephedrine Approved Phase 4 299-42-3 9294
7
Phenylephrine Approved Phase 4 59-42-7 6041
8
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 137-58-6 3676
9
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
10
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
11
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
12 tannic acid Approved Phase 4,Phase 3,Not Applicable
13
Pseudoephedrine Approved Phase 4 90-82-4 7028
14
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
15
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 2,Early Phase 1,Not Applicable 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Early Phase 1,Not Applicable 50-23-7 5754
17
Hydrogen peroxide Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 7722-84-1 784
18
Diclofenac Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 15307-86-5 3033
19
Piroxicam Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 36322-90-4 54676228 5280452
20
Clindamycin Approved, Vet_approved Phase 4,Not Applicable 18323-44-9 29029
21
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 26787-78-0 33613
22
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 69-72-7 338
23
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Not Applicable 15687-27-1 3672
24
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 537-46-2 10836
25
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-61-6, 62-31-7 681
26
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable,Early Phase 1 22916-47-8 4189
27
Sorbitol Approved Phase 4,Phase 2,Phase 3,Not Applicable 50-70-4 5780
28
Ethanol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 64-17-5 702
29
Zinc Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 1177-87-3
31
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-02-2 5743
32
Ketamine Approved, Vet_approved Phase 4,Phase 2 6740-88-1 3821
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 93-14-1 3516
34
Codeine Approved, Illicit Phase 4,Phase 3,Phase 2 76-57-3 5284371
35
Esomeprazole Approved, Investigational Phase 4,Phase 1,Phase 2 161796-78-7, 119141-88-7 4594 9579578
36
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 22204-53-1 1302 156391
37
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
38
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
39
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3 302-25-0
40
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
41
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3 2921-57-5
42
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
43
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3 59467-70-8 4192
44
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 27203-92-5 33741
45
Mepivacaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 96-88-8 4062
46
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
47
Silicon Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-21-3 4082203
48
Alginic acid Approved, Investigational Phase 4,Not Applicable 9005-32-7
49
Cetylpyridinium Approved Phase 4,Phase 3,Phase 2,Phase 1 7773-52-6
50
Triclosan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 3380-34-5 5564

Interventional clinical trials:

(show top 50) (show all 1548)
# Name Status NCT ID Phase Drugs
1 TM vs TSV Implants Loaded Early vs Conventional in Anterior and Posterior Areas Unknown status NCT02158377 Phase 4
2 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
3 Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT Unknown status NCT02702505 Phase 4
4 Study of the Safety and Efficacy of Botox in Bruxism Unknown status NCT00908050 Phase 4 Botulinum toxin type A
5 Effectiveness of Nanohydroxyapetite Paste on Reducing Dentin Hypersensitivity Unknown status NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
6 Effect of Different Mouthrinses in Plaque Formation Unknown status NCT02695901 Phase 4 Chlorhexidine gluconate 0.12% (PerioGard®);Nanoparticle solution of M. alternifolia oil (0.3%).
7 Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children. Unknown status NCT02692625 Phase 4
8 Dental Caries Management by Risk Assessment: Identification and Treatment of Risk Factors Among (IDF) Personnel Unknown status NCT01142440 Phase 4
9 Manually Versus Digitally Fabricated Removable Partial Dentures Unknown status NCT01191073 Phase 4
10 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
11 Clinical Comparison of RPDs Retained by Conical and Galvanoformed Double Crowns. Unknown status NCT00176215 Phase 4
12 Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins Unknown status NCT02449707 Phase 4
13 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
14 Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). Unknown status NCT01778699 Phase 4
15 Efficacy of Different Chlorhexidine Concentrations Unknown status NCT02911766 Phase 4 Chlorhexidine 0.2% Mouthrinse;Chlorhexidine 0.12% mouthrinse;Chlorhexidine 0.06% mouthrinse
16 Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel Unknown status NCT00846690 Phase 4 benzocaine;TAC alternate gel
17 Ketamine on Acute Pain in Females and Males Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
18 Topical Hydrocortisone for Pain and Edema Control After Third Molar Surgery Completed NCT03179813 Phase 4
19 The Effect of Whitening Toothpaste on Tooth Color Associated With Bleaching Process Completed NCT03163069 Phase 4
20 Efficacy of a Whitening Dentifrice on Tooth Discoloration Completed NCT02741427 Phase 4
21 Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction. Completed NCT02547896 Phase 4 Codeine + Diclofenac;Diclofenac
22 Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal Completed NCT02494856 Phase 4 Surgery with Naproxen;Surgery with Naproxen and Esomeprazole
23 Lower Third Molar Removal With 2% and 4% Articaine Completed NCT02457325 Phase 4 Surgery with 2% articaine;Surgery with 4% articaine
24 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery Completed NCT02450487 Phase 4 Piroxicam
25 AUGMENTINâ„¢ in Dental Infections Completed NCT02141217 Phase 4 Amoxicillin/clavulanate;Clindamycin
26 Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients Completed NCT02017873 Phase 4 Peroxide Carbamide 10% - Dental bleaching treatment
27 An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining Completed NCT01962493 Phase 4 Chlorhexidine digluconate
28 Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners Completed NCT01962012 Phase 4
29 Clinical Effectiveness of In-office Bleaching Activated With a LED/Laser Device Completed NCT01231243 Phase 4
30 BiodentineTM Versus Formocresol Pulpotomy Technique in Primary Molars Completed NCT03779698 Phase 4 Formocresol
31 Indirect Pulp Treatment in Primary Molars Completed NCT03770871 Phase 4 Dycal (Indirect pulp treatment);Vitrebond (Indirect pulp treatment)
32 Effectiveness of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders Completed NCT03533335 Phase 4
33 Effect of the Amount of Fluoride Toothpaste on Fluoride Availability in the Oral Fluids in Children Completed NCT03455621 Phase 4
34 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
35 Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks Completed NCT03426150 Phase 4 CPP-ACP;Placebos
36 Treatment of Immature Permanent Teeth With Three Different Pulp Capping Materials With Partial Pulpotomy Completed NCT03426046 Phase 4 Pulp Capping Agents
37 The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Completed NCT02953886 Phase 4
38 To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH) Completed NCT02923895 Phase 4
39 Nano-hydroxyapatite With Potassium Nitrate in the Therapy of the Dental Sensitivity Completed NCT02895321 Phase 4
40 Oral Glucocorticoids Effect on Post Endodontic Pain Completed NCT02819648 Phase 4 Prednisolone
41 Fuji Type VII Sealant Versus Resin Based Sealant. A Clinical Trial Completed NCT02795728 Phase 4
42 Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity Completed NCT02773758 Phase 4
43 Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02731833 Phase 4
44 Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars Completed NCT02592278 Phase 4 Fluoride Varnish;Control Group
45 Comparison of the Effect of Fluoride Remineralizer Gel and Foam Completed NCT02490592 Phase 4
46 Clinical Study of the Whitening Dentifrices on Tooth Color and Sensitivity Completed NCT02483013 Phase 4
47 Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment Completed NCT02447289 Phase 4 Intranasal ketamine;Oral ketamine;Intranasal midazolam;Oral midazolam
48 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
49 Preventive and Therapeutic Proximal Sealants Completed NCT02338180 Phase 4
50 The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching Completed NCT02316080 Phase 4

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: tooth diseases

Sources

Genetic Tests for Tooth Disease

About this section
Sources

Anatomical Context for Tooth Disease

About this section

MalaCards organs/tissues related to Tooth Disease:

41
Testes, Brain, Lung, Liver, Bone, Spinal Cord, Skeletal Muscle
Sources

Publications for Tooth Disease

About this section

Articles related to Tooth Disease:

(show top 50) (show all 1274)
# Title Authors Year
1
Coexistence of Amyotrophic Lateral Sclerosis in the Proband of an X-Linked Charcot-Marie-Tooth Disease Type 1 Pedigree in China. ( 29629536 )
2018
2
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [commentary]. ( 29289585 )
2018
3
Clinical and genetic features of Charcot-Marie-Tooth disease 2F and hereditary motor neuropathy 2B in Japan. ( 29381233 )
2018
4
Myelinated axons fail to develop properly in a genetically authentic mouse model of Charcot-Marie-Tooth disease type 2E. ( 29940160 )
2018
5
Pain in Charcot-Marie-Tooth disease: an update. ( 29742248 )
2018
6
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease. ( 29415205 )
2018
7
Six months of strength training reduces progression of dorsiflexor muscle weakness in children with Charcot-Marie-Tooth disease [synopsis]. ( 29276065 )
2018
8
Evaluation of muscle strength, balance and functionality of individuals with type 2 Charcot-Marie-Tooth Disease. ( 29674285 )
2018
9
MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. ( 29674596 )
2018
10
Clinical and genetic investigation in Chinese patients with demyelinating Charcot-Marie-Tooth disease. ( 29896895 )
2018
11
DHTKD1 Deficiency Causes Charcot-Marie-Tooth Disease in Mice. ( 29661920 )
2018
12
Charcot-Marie-Tooth disease type 2A with an autosomal-recessive inheritance: the first report of an adult-onset disease. ( 29215088 )
2018
13
Drosophila Charcot-Marie-Tooth Disease Models. ( 29951817 )
2018
14
A novel mutation of LRSAM1 in a Chinese family with Charcot-Marie-Tooth disease. ( 29341362 )
2018
15
Association of miR-149 polymorphism with onset age and severity in Charcot-Marie-Tooth disease type 1A. ( 29729827 )
2018
16
Antineoplastic agents exacerbating Charcot Marie Tooth disease: red flags to avoid permanent disability. ( 29243538 )
2018
17
HADHB mutations cause infantile-onset axonal Charcot-Marie-Tooth disease: A report of two cases. ( 29956646 )
2018
18
Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot-Marie-Tooth disease family. ( 29341343 )
2018
19
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
20
Myelin protein zero mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. ( 29687021 )
2018
21
Neurofilament light, biomarkers, and Charcot-Marie-Tooth disease. ( 29321227 )
2018
22
PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models. ( 29202483 )
2018
23
Cochlear Implantation in Charcot-Marie-Tooth Disease: Case Report and Review of the Literature. ( 29780422 )
2018
24
Substitution impact of highly conserved arginine residue at position 75 in GJB1 gene in association with X-linked Charcot-Marie-tooth disease: A computational study. ( 29111421 )
2018
25
A novel homozygous NDRG1 mutation in a Chinese patient with Charcot-Marie-Tooth disease 4D. ( 29724652 )
2018
26
Genetic analysis of Charcot-Marie-Tooth disease in Denmark and the implementation of a next generation sequencing platform. ( 29653220 )
2018
27
Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. ( 29729594 )
2018
28
Clinical and genetic diversities of Charcot-Marie-Tooth disease with MFN2 mutations in a large case study. ( 29906321 )
2018
29
MARS variant associated with both recessive interstitial lung and liver disease and dominant Charcot-Marie-Tooth disease. ( 29655802 )
2018
30
PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease. ( 29449460 )
2018
31
Operative treatment algorithm for foot deformities in Charcot-Marie-Tooth disease. ( 29417158 )
2018
32
The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study. ( 29136549 )
2018
33
Peripheral neuropathies: Antisense therapy for Charcot-Marie-Tooth disease? ( 29269786 )
2018
34
Testing overwork weakness in Charcot-Marie-tooth disease: Is it true or false? ( 29693294 )
2018
35
Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs. ( 29276154 )
2018
36
Anaesthesia and orphan diseases: anaesthetic management of a patient with X-linked Charcot-Marie-Tooth disease type 1. ( 29870477 )
2018
37
BAG3 mutation in a patient with atypical phenotypes of myofibrillar myopathy and Charcot-Marie-Tooth disease. ( 30145633 )
2018
38
X-linked Charcot-Marie-Tooth disease type 5 with recurrent weakness after febrile illness. ( 30177296 )
2018
39
X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. ( 30196252 )
2018
40
Developing Charcot-Marie-Tooth Disease Recognition System Using Bacterial Foraging Optimization Algorithm Based Spiking Neural Network. ( 30203246 )
2018
41
Nerve ultrasound findings differentiate Charcot-Marie-Tooth disease (CMT) 1A from other demyelinating CMTs. ( 30216910 )
2018
42
Genetic profile and onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan. ( 30257968 )
2018
43
MRI of the anterior compartment of the lower leg is a biomarker for weakness, disability and impaired gait in childhood Charcot-Marie-Tooth disease. ( 30265406 )
2018
44
Membranous Nephropathy in a Patient with Charcot-Marie-Tooth Disease: Association of Myelin Mutations. ( 30271005 )
2018
45
Hand Rehabilitation Treatment for Charcot-Marie-Tooth Disease: An Open Label Pilot Study. ( 30305981 )
2018
46
Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. ( 30334469 )
2018
47
Novel GARS mutation presenting as autosomal dominant intermediate Charcot-Marie-Tooth disease. ( 30394614 )
2018
48
Charcot Marie Tooth disease type 2S with late onset diaphragmatic weakness: An atypical case. ( 30409445 )
2018
49
An In Vitro Model of Charcot-Marie-Tooth Disease Type 4B2 Provides Insight Into the Roles of MTMR13 and MTMR2 in Schwann Cell Myelination. ( 30419760 )
2018
50
Development and validation of the Charcot-Marie-Tooth Disease Infant Scale. ( 30476010 )
2018
Sources

Variations for Tooth Disease

About this section
Sources

Expression for Tooth Disease

About this section
Search GEO for disease gene expression data for Tooth Disease.
Sources

Pathways for Tooth Disease

About this section

Pathways related to Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neural Crest Differentiation 1
10.81 GJB1 MPZ PMP22
Sources

GO Terms for Tooth Disease

About this section

Cellular components related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 FGD4 GDAP1 HSPB1 HSPB8 LITAF LMNA
2 myelin sheath GO:0043209 9.43 MPZ NDRG1 NEFL
3 vacuolar membrane GO:0005774 9.37 MTMR2 SBF2
4 early endosome membrane GO:0031901 9.33 FIG4 LITAF MTMR2
5 axon cytoplasm GO:1904115 8.8 HSPB1 KIF1B NEFL
6 cytoplasm GO:0005737 10.13 EGR2 FGD4 GDAP1 GJB1 HSPB1 HSPB8

Biological processes related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peripheral nervous system development GO:0007422 9.43 EGR2 PMP22
2 phosphatidylinositol metabolic process GO:0046488 9.4 FIG4 MTMR2
3 mitochondrial fusion GO:0008053 9.37 GDAP1 MFN2
4 negative regulation of endocytosis GO:0045806 9.32 LRSAM1 MTMR2
5 peripheral nervous system myelin maintenance GO:0032287 9.26 NDRG1 SH3TC2
6 myelination GO:0042552 9.26 EGR2 MPZ PMP22 SBF2
7 negative regulation of myelination GO:0031642 9.16 FIG4 MTMR2
8 myelin assembly GO:0032288 8.8 FIG4 MTMR2 PMP22

Molecular functions related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-3-phosphatase activity GO:0004438 8.62 FIG4 MTMR2
Sources

Sources for Tooth Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....